Navigation Links
New sickle cell anemia therapy advances to Phase II clinical trials
Date:6/12/2013

SAN DIEGO (June 12, 2013) Seeking to improve the lives of sickle cell anemia sufferers around the world, researchers from the La Jolla Institute for Allergy and Immunology, the Dana-Farber/Children's Hospital Cancer Center in Boston and the BloodCenter of Wisconsin in Milwaukee and others are preparing to launch Phase II of a clinical trial to investigate a potential new therapy for reducing the disorder's severest symptoms. Sickle cell anemia is a serious, painful and chronic illness that impedes blood flow and can lead to early death. More than 100,000 Americans and several million people worldwide suffer from this genetic disorder.

The phase II trial, funded by a $10.8 million grant from the National Institutes of Health, is testing an already existing drug called Lexiscan (regadenoson - Astellas Pharma US, Inc.), which is used for diagnosing heart disease. Researchers are exploring whether the drug's anti-inflammatory effects will significantly reduce the pain and blood flow disturbances of sickle cell anemia. A Phase I safety study was completed earlier this year. Recruitment is now under way for the trial's second phase to be conducted at treatment centers in eight major U.S. cities: Boston, Baltimore, Detroit, Chicago, Cincinnati, Milwaukee, Chapel Hill, and St. Louis.

"We are excited to begin the next phase of investigating Lexiscan's potential for reducing inflammation that contributes to the poor blood flow and serious complications of sickle cell disease," says La Jolla Institute scientist Joel Linden, Ph.D., a prominent researcher whose studies laid the groundwork for the trial. "Our phase I results were promising. Participants experienced no adverse reactions and our tests indicated that the drug significantly reduces inflammation. It is too early to tell whether this will translate into reduced pain and tissue damage. But we remain cautiously optimistic." The Phase I results were published as the cover article in th
'/>"/>

Contact: Bonnie Ward
contact@liai.org
619-303-3160
La Jolla Institute for Allergy and Immunology
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Sickle cell trait can cause sudden cardiac death in black athletes: Why is this controversial?
2. Potential gene therapy approach to sickle cell disease highlighted at ASH
3. Nature study reveals loss of essential blood cell gene leads to anemia
4. Why a hereditary anemia is caused by genetic mutation in mechanically sensitive ion channel
5. Cleveland Clinic research shows anemia drug does not improve health of anemic heart failure patients
6. Discovery may help prevent chemotherapy-induced anemia
7. Scientists identify potential drug target for treatment-resistant anemias
8. Stanford scientists develop gene therapy approach to grow blood vessels in ischemic limbs
9. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
10. New insight into mechanisms behind autoimmune diseases suggests a potential therapy
11. The Japanese traditional therapy, honokiol, blocks key protein in inflammatory brain damage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... NY (July 24, 2014) Scientists at The ... are one step closer to creating a viable ... patient,s own cells. , For the first ... cells lines from skin samples of patients with ... an accelerated protocol to induce these stem cells ...
(Date:7/24/2014)... factors that characterize sustainable university and college programs ... physics teachers. Specifically, one or more faculty members ... combination with institutional motivation and commitment can ensure ... and Math (STEM) teacher shortages are especially acute ... for institutions seeking to increase the number of ...
(Date:7/24/2014)... A sake brewery has its own microbial terroir, meaning ... resemble those found in the product, creating the final ... the journal Applied and Environmental Microbiology . This ... census of a sake brewery. , Many sake ... author David A. Mills of the University of California, ...
Breaking Biology News(10 mins):NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2Creating sustainable STEM teacher preparation programs 2The microbes make the sake brewery 2
... Maine Toxicity (GOMTOX) project issued an outlook for a significant ... tides, in the spring and summer of this year, potentially ... seed population in bottom sediments has set the stage for ... This organism swims in the water, and divides again and ...
... Bacteria in Cattle Manure May Survive Composting ... may actually survive the composting process. Researchers from Agriculture ... of the journal Applied and Environmental Microbiology ... and persist for long periods in the final product. ...
... The squirrels littering your lawn with acorns as they bound ... ones that aerate it with their burrows, according to a ... that flying birds and bats live longer than earthbound animals ... candidates in anthropology, decided to take a closer look at ...
Cached Biology News:Researchers issue outlook for a significant New England 'red tide' in 2010 2Researchers issue outlook for a significant New England 'red tide' in 2010 3Tips from the Journals of the American Society for Microbiology 2Tips from the Journals of the American Society for Microbiology 3Tips from the Journals of the American Society for Microbiology 4Tree-dwelling mammals climb to the heights of longevity 2
(Date:7/24/2014)... most natural and synthetic processes prefer to settle ... or energyit is within the realm of non-equilibrium ... constant changes in energy and phases, such as ... conditions allow humans to regulate their body temperature, ... with seismic activity. , But even though ...
(Date:7/24/2014)... 24, 2014 SRI International has been awarded ... Institute of Allergy and Infectious Diseases (NIAID), part of ... of potential therapies for HIV infection and AIDS. The ... and AIDS and the complications and opportunistic infections associated ... sexual transmission of HIV. According to ...
(Date:7/24/2014)... 24, 2014  Neogen Corporation (Nasdaq: NEOG ... its potential revenue from new rodenticide research are premature. ... analysts on July 22, 2014, Neogen,s CEO commented about ... research. "It was my intent Tuesday at ... of a new type of rodenticide, but certainly not ...
(Date:7/24/2014)... Draper University, a top program ... announce that for 6 weeks this summer, 39 ... on the Draper University campus in the heart ... focused on entrepreneurship, building real-world skills, and “learning ... its sixth cohort, continues to refresh its curriculum ...
Breaking Biology Technology:New approach to form non-equilibrium structures 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3Neogen comments on SenesTech 2Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 2Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 3
... SOUTH SAN FRANCISCO, Calif., May 15 Poniard Pharmaceuticals, ... focused on oncology, today announced that it has filed ... Securities and Exchange Commission (SEC) that, when declared effective ... time to offer and sell up to $60 million ...
... JOLLA, Calif., May 15 Fate Therapeutics, ... exclusive intellectual property rights jointly owned by Children,s Hospital ... covers compositions and methods for supporting hematopoietic stem cells. ... director of the Stem Cell Program at Children,s Hospital ...
... Shandong, China, May 15 /PRNewswire-Asia-FirstCall/ -- China,Biologic Products, ... the,Company,), one of the leading plasma-based pharmaceutical companies ... that the Company,s,management will present at the upcoming ... New York, NY on May 18, 2009 and ...
Cached Biology Technology:Poniard Pharmaceuticals Files Shelf Registration 2Poniard Pharmaceuticals Files Shelf Registration 3Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Children's Hospital Boston and Massachusetts General Hospital 2Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Children's Hospital Boston and Massachusetts General Hospital 3China Biologic Products to Present at CCG IR's China Rising Conference and Oppenheimer's China Dragon Call Conference in New York 2China Biologic Products to Present at CCG IR's China Rising Conference and Oppenheimer's China Dragon Call Conference in New York 3China Biologic Products to Present at CCG IR's China Rising Conference and Oppenheimer's China Dragon Call Conference in New York 4
... increasing age, the autofluorescent pigment lipofuscin ... cell types, including neurons. The presence ... use of fluorescence microscopy in the ... broad excitation and emission spectra, which ...
One unit is equal to 10Kb (insert DNA + vector). The final cost will increase or decrease according to the final assembled genome size. The price does not include genome annotation....
... to the family of calcium binding proteins such ... composed of an alpha and beta chain whereas ... S100 protein is also expressed in the antigen ... skin and interdigitating reticulum cells in the paracortex ...
Polyclonal Antibody to Golgin-67...
Biology Products: